Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.75
Bid: 18.00
Ask: 19.50
Change: 0.25 (1.35%)
Spread: 1.50 (8.333%)
Open: 18.50
High: 19.50
Low: 17.75
Prev. Close: 18.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Bens Creek considers administration; Nexxen inks deal

Thu, 16th May 2024 20:09

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Bens Creek Group PLC - owner and operator of metallurgical coal mines across North America - Requests suspension of trading in company's shares. This follows the receipt on Wednesday of a redemption notice from ACAM GP Ltd, in its capacity as general partner of ACAM LP. Explains the notice is for the redemption of the principal and outstanding interest pursuant to the around USD7.57 million of unsecured loan notes Bens Creek issued to ACAM, as announced in July 2023. As announced last Friday, company is severely cash constrained. As a result, it is unable to repay the amount due to ACAM. Therefore, considers options available, which may include appointing administrators.

----------

EnergyPathways PLC - West Sussex, England-based energy company primarily focused on developing the Marram Field offshore gas project - Continues to make solid progress on the planned development of its flagship Marram energy storage project which targets first gas in 2025. Says "Out of Round" requests for gas production and gas storage licences are progressing with the North Sea Transition Authority. But notes the company was outbid for the Castletown discovery block application made in the 33rd licensing round. Adds talks are progressing with a major regional wind company for the supply of renewable wind power to the Marram Project and an expanded UK Irish Sea energy storage project. Further, says talks are progressing well on both debt and equity financing.

----------

Horizonte Minerals PLC - nickel development company focused on projects in Para State, Brazil - Requests suspension of trading in company's shares on Thursday. Explains, as per announcement in April, it has been unable to secure interest in the full financing needed to complete its 100% owned Araguaia nickel project. Regrettably concludes that Horizonte should be placed into administration in order to seek to preserve the value of the business for creditors and other stakeholders. Appoints Geoff Rowley and Chad Griffin of FRP Advisory as administrators.

----------

SolGold PLC - Ecuador-focused copper and gold exploration company - In the three months to March 31, pretax loss widens USD30.8 million from USD23.2 million a year prior. This includes USD24.1 million remeasurement of amortised cost of financial liability versus zero the year before. Losses per diluted share are 1.0 US cents compared to 1.1 cents.

----------

Angle PLC - Guildford, England-based liquid biopsy company - Announces the publication of a study using the Parsortix system to identify markers present in circulating tumour cells harvested from metastatic mutant-p53 platinum-resistant ovarian cancer patients. The study was conducted as an offshoot of the European multi-centre GANNET53 Phase II clinical trial and investigated the efficacy of ganetespib in combination with paclitaxel versus paclitaxel alone. Patients were enrolled across 12 clinical centres in Germany, Belgium, France, and Austria. The study identified two CTC-associated markers with potential prognostic value. Says the analysis of these biomarkers has the potential to provide an early indication of progression free survival ahead of clinical trial results and suggests that CTC characterisation may be a valuable tool for pharma drug trials in the future.

----------

Oxford BioDynamics PLC - Oxford-based biotechnology company - Announces it is collaborating with King's College, University of London, in the immediate follow up of the APIPPRA trial, the largest rheumatoid arthritis prevention trial to date. Break-through results of the trial were recently published in The Lancet in February. Points out 25% of treated patients who initially showed response subsequently developed RA. King's College is now collaborating with Oxford BioDynamics, to develop prognostic and predictive blood-based EpiSwitch biomarkers to identify patients at risk of RA who can benefit from treatment.

----------

Hellenic Dynamics PLC - Greece-based cultivator and supplier of pharmaceutical standard medical cannabis products - Enters deed of amendment with RiverFort Global Opportunities PCC Ltd in respect of its unsecured mezzanine loan facility of up to USD3 million announced in October. Under the terms of the facility, Hellenic was required to maintain sufficient headroom to be able to satisfy the outstanding balance of the facility by the issue of new ordinary shares in the company, if not repaid in cash. Following the recent fundraise, Hellenic and Riverfort have agreed to amend the facility to allow the placing to take proceed. The June to September repayments will be deferred. In return, Riverfort charges additional fee of 10% of outstanding balance.

----------

Upland Resources Ltd - Jersey-based oil and gas company focused on Sarawak, Malaysia - Following the meeting with key heads of Sarawak State in London in April, confirms that a number of meetings have been held in Kuching this week with key officials of Sarawak State and with Petroleum Sarawak. Discussions have been to finalise Upland's application for a petroleum sharing contract. Further, confirms that it is now in discussions with five established exploration and production companies, including oil & gas majors to participate in the exploration and production of Block SK334. Signs two letters of intent on potential joint venture, farm-in agreements. Actively determining which of the current options will provide the best shareholder value. Chair and Chief Executive Bolhassan Di says: "As we would expect the potential of SK334 is attracting a lot of attention and we already have some very serious alternatives to consider. We do expect there to be a lot more interest and as a company we will make sure that the options we choose move us ahead but also are in the long-term interests of all our stakeholders." Further, names Albert May as chief commercial officer from May 1.

----------

Nexxen International Ltd - Tel Aviv-based advertising technology platform - Announces a partnership with Nasdaq listed, Stagwell Inc to offer data solutions and integrated applications within the Stagwell Marketing Cloud.

----------

Murray International Trust PLC - Edinburgh-based investment trust, managed by abrdn PLC - Repays its maturing GBP30 million 5 year fixed rate loan with The Royal Bank of Scotland International Ltd. Following the repayment, borrowings consist of GBP50 million in unsecured loan notes, maturing in May 2031 and GBP60 million in unsecured loan notes maturing in May 2037. The weighted cost of borrowing based on these borrowings will be 2.56%.

----------

UK Commercial Property REIT Ltd - UK-focused commercial property investor - Says scheme of arrangement by which merger with Tritax Big Box REIT will be facilitated becomes effective. Says dealings in company's shares suspended Thursday and shares will be cancelled Friday.

----------

Aviva PLC - London-based insurer - Gives notice to the holders of the EUR700 million 3.875% dated Tier 2 reset notes that Aviva will redeem the notes in full on July 3.

----------

Gresham Technologies PLC - London-based software and services for data integrity and financial management - Court Meeting and General Meeting held on Thursday approve the scheme of arrangement by which the bid for Gresham by STG Partners LLC will be made. In April, Gresham agreed to a nearly GBP150 million takeover offer from funds advised by private equity firm STG. Shareholders will be receive 163 pence per share in cash. Gresham also plans to pay an interim dividend for 2023 of 0.75p per share, taking the total offer value to 163.75p per share.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
16 May 2024 11:46

Angle reports promising results from Parsortix study

(Sharecast News) - Angle, the AIM-listed liquid biopsy company which specialises in circulating tumour cell (CTC) solutions, has announced the results of a clinical study which show that its Parsortix system could be used to predict progression-free survival in patients with ovarian cancer.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 10:52

AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
3 May 2024 08:48

LONDON MARKET OPEN: Confident start before US jobs data

(Alliance News) - Stock prices in London opened higher on Friday, on the rising conviction that the afternoon's US jobs report will be softer, cooling some hawkish Federal Reserve interest rate expectations.

Read more
3 May 2024 07:58

Angle strikes supplier deal with AstraZeneca

(Sharecast News) - Liquid biopsy technology firm Angle has struck a supplier deal with pharmaceutical giant AstraZeneca to develop an androgen receptor detection assay to enhance prostate cancer studies.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
24 Apr 2024 17:06

CORRECT: No record close for FTSE 100; mixed trade in US

(Correcting day of the week in the opening sentence.)

Read more
24 Apr 2024 17:00

LONDON MARKET CLOSE: No record close for FTSE 100; mixed trade in US

(Alliance News) - Stock prices in London closed lower on Thursday, with the FTSE 100's recent rally taking a pause for breath, but not after hitting another record high.

Read more
24 Apr 2024 10:32

Angle shares jump on supplier agreement with with AstraZeneca

(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC.

Read more
24 Apr 2024 10:10

AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
22 Apr 2024 16:52

IN BRIEF: Angle granted patents in US and Europe for Cellkeep slide

Angle PLC - Surrey-based medical diagnostics provider - Says it has been granted a European and US patent for its CellKeep slide. "We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions....This is a significant technology advancement for the [circulating tumor cell] liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer," says Chief Executive Officer Andrew Newland. The CellKeep slide was developed by Angle to reduce cell loss during the transfer of CTCs to the microscope slide and to protect the morphology of the harvested cells.

Read more
22 Apr 2024 06:59

Angle granted European patent for CellKeep, US patent imminent

(Sharecast News) - Liquid biopsy specialist Angle announced on Monday that it has received a European patent for its 'CellKeep' slide, as it anticipated the imminent grant of an equivalent US patent application.

Read more
22 Jan 2024 18:03

IN BRIEF: Angle highlights supportive data for DNA analysis tool

Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.